CLOT IN BLOOD VESSELS

  • astrazeneca reaffirms vaccine safety amidst rare side effect concerns

    AstraZeneca reaffirms vaccine safety amidst rare side effect concerns

    ​The Serum Institute of India produced COVID-19 vaccine named Covishield but not using mRNA platform. It has been prepared using the viral vector platform. In the vaccine, a chimpanzee adenovirus - ChAdOx1 - has been modified to enable it to carry the COVID-19 spike protein into the cells of humans. This cold virus is basically incapable of infecting the receiver, but can very well teach the immune system to prepare a mechanism against such viruses.

Join the community of 2M+ industry professionals

Subscribe to our Daily Newsletter

By continuing you agree to our Privacy Policy & Terms & Conditions

Scan to download App

Download ETHealthworld App for Realtime updates of content you follow

  • Seamless reading experience
  • Save your favourite articles
Advertisement
Advertisement